Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at CTAD 2025
Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Fujitsu establishes international consortium to tackle disinformation/misinformation and new AI risks
Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms
Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials
Fujitsu launches ‘Fujitsu Accelerator Program for SPORTS’ to create new value through Sports x Technology
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI(R)” for the Treatment of Early Alzheimer’s Disease in Japan
Sharp Wins IAM’s “Asia IP Elite 2025”, Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
